• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 29, 2014

View Archived Issues

Acelrx Pharma pounded after surprise CRL for Zalviso pain management product

Acelrx Pharmaceuticals Inc. didn't have to wait for its Sunday PDUFA date for Zalviso, but the company also didn't receive the FDA approval it sought and analysts largely expected. Instead, the FDA late Friday issued a complete response letter (CRL) for the pain management product, seeking more information about the device to ensure proper use. Read More

Limited 'Horizon'? PBMs may eliminate drug pair from formularies in 2015

Word that a pair of pharmacy benefit managers (PBMs) may drop two nonsteroidal anti-inflammatory drugs (NSAIDs) from their formularies sent Horizon Pharma Inc. shares into a tailspin and caused onlookers to speculate about further pushbacks from payers and their agents against high drug prices. Read More

Paxvax steers commercial course with Vivotif buy and $62M financing

In a two-step scheme, specialty vaccine developer Paxvax Inc. acquired the FDA-approved oral typhoid vaccine Vivotif from Crucell Switzerland AG and financed the deal with $50 million in secured debt from an investment fund managed by Pharmakon Advisors and $12 million in an extension of its series B preferred stock. The Redwood City, Calif.-based company, whose lead product is a single-dose cholera vaccine in a phase III program, now takes up the challenge of transforming from a small biotech to a commercial venture. Read More

Another filgrastim approved as EMA adds to biosimilar list

LONDON – The EMA added an eighth product to the roster of biosimilar versions of Amgen Inc.’s Neupogen it has approved, giving the nod to Accofil from Accord Healthcare Ltd., of Haverhill, UK. Read More

2nd Zealand, Boehringer Ingelheim diabetes deal worth up to $396M

Zealand Pharma A/S could earn up to €295 million (US$396 million) in milestone payments arising from a second drug development deal in diabetes with Boehringer Ingelheim GmbH. It will bank €5.6 million during 2014. Read More

Researchers discover genetic cause of common breast tumors

HONG KONG – A multidisciplinary research team from Singapore has made a significant breakthrough in the understanding of the molecular basis of benign fibroadenomas, one of the most common breast tumors in women, which could have important implications for the diagnosis and treatment of malignant breast cancers. Read More

Former Lumena CEO talks recent Shire deal, new opportunitie

Lumena Pharmaceuticals Inc. hit the ground running when it was founded three years ago and in-licensed programs aimed at rare liver diseases. Read More

News from Washington

Responding to citizen petitions filed by Abbvie Inc., of North Chicago, and Auxilium Pharmaceuticals Inc., of Chesterbrook, Pa., the FDA said it doesn't need to do a rulemaking to assign a therapeutic equivalency (TE) rating to testosterone drugs approved on the 505(b)(2) path. Read More

Other news to note

Morphosys AG, of Martinsried, Germany, provided an update on its candidate portfolio, placing a priority on phase II data in non-Hodgkin's lymphoma by the end of this year with MOR208, an anti-CD19 antibody. Read More

Stock movers

Read More

In the clinic

Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said it completed patient enrollment in IGNITE 1, its phase III trial evaluating the safety and efficacy of eravacycline in the treatment of complicated intra-abdominal infections (cIAIs). Read More

Pharma: Other news to note

Aqua Pharmaceuticals, of West Chester, Pa., a subsidiary of Almirall SA, said the FDA approved Acticlate (doxycycline hyclate USP) tablets, 150 mg and 75 mg. Read More

Pharma: In the clinic

Janssen R&D Ireland, of Cork, Ireland, and Medivir AB, of Huddinge, Sweden, said results from the phase II COSMOS study were published in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir, an NS3/4A protease inhibitor, in combination with sofosbuvir (Gilead Sciences Inc.), achieved sustained virologic response 12 weeks after the end of treatment, including those patients with compensated cirrhosis and prior null response to treatment with pegylated interferon and ribavirin. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe